Modulation of thalidomide pharmacokinetics by cyclophosphamide or 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice: The role of tumour necrosis factor

Cancer Chemotherapy and Pharmacology

Volumn 53, Issue 5, 2004, Pages 377-383

  Chung, Francisco ^a   Wang, Liang Chuan S ^a   Kestell, Philip ^a   Baguley, Bruce C ^a   Ching, Lai Ming ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Cyclophosphamide; DMXAA; Pharmacokinetics; Thalidomide; TNF

Indexed keywords

5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; CYCLOPHOSPHAMIDE; THALIDOMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; COLON TUMOR; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG POTENTIATION; DRUG TISSUE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; AREA UNDER CURVE; CYCLOPHOSPHAMIDE; DRUG INTERACTIONS; MICE; MICE, INBRED C57BL; THALIDOMIDE; TUMOR NECROSIS FACTOR-ALPHA; XANTHONES;

EID: 2142714499     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-003-0753-2     Document Type: Article

References (28)

1. Ando Y, Fuse E, Figg WD (2002) Thalidomide metabolism by the CYP2C subfamily. Clin Cancer Res 8:1964
2. Cao Z, Joseph WR, Browne WL, Mountjoy KG, Palmer BD, Baguley BC, Ching LM (1999) Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4- acetic acid. Br J Cancer 80:716
3. Cao Z, Baguley BC, Ching LM (2001) Interferon-inducible protein 10 induction and inhibition of angiogenesis in vivo by the antitumor agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Res 61:1517
4. Ching LM, Xu ZF, Gummer BH, Palmer BD, Joseph WR, Baguley BC (1995) Effect of thalidomide on tumour necrosis factor production and anti-tumour activity induced by 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer 72:339
5. Ching LM, Cao Z, Kieda C, Zwain S, Jameson MB, Baguley BC (2002) Induction of endothelial cell apoptosis by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer 86:1937
6. D'Amato RJ, Loughnan MS, Flynn E, Folkman J (1994) Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91:4082
7. DeLeve LD (1996) Cellular target of cyclophosphamide toxicity in the murine liver: role of glutathione and site of metabolic activation. Hepatology 24:830
8. Ding Q, Kestell P, Baguley BC, Palmer BD, Paxton JW, Muller G, Ching LM (2002) Potentiation of the antitumour effect of cyclophosphamide in mice by thalidomide. Cancer Chemother Pharmacol 50:186
9. Eisen T, Boshoff C, Mak I, Sapunar F, Vaughan MM, Pyle L, Johnston SR, Ahern R, Smith IE, Gore ME (2000) Continuous low dose thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer 82:812
10. Garcia-Sanz R, Gonzalez-Fraile MI, Sierra M, Lopez C, Gonzalez M, San Miguel JF (2002) The combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is feasible and can be an option for relapsed/refractory multiple myeloma. Hematol J 3:43
11. Hill GR, Cooke KR, Brinson YS, Bungard D, Ferrara JL (1999) Pretransplant chemotherapy reduces inflammatory cytokine production and acute graft-versus-host disease after allogeneic bone marrow transplantation. Transplantation 67:1478
12. Kestell P, Zhao L, Baguley BC, Palmer BD, Muller G, Paxton JW, Ching LM (2000) Modulation of the pharmacokinetics of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice by thalidomide. Cancer Chemother Pharmacol 46:135
13. Lee SY, Lim JW, Kim YM (2001) Effect of alphal-acid glycoprotein expressed in cancer cells on malignant characteristics. Mol Cells 11:341
14. Lee Y, Lim JW, Kim YM, Lee IH, Choi YC, Park KC (2001) Induction of alphal-acid glycoprotein mRNA by cytokines and differentiation in human colon carcinoma cell. Mol Cells 11:164
15. Lu J, Palmer BD, Kestell P, Browett P, Baguley BC, Muller G, Ching LM (2003) Thalidomide metabolites in mice and patients with multiple myeloma. Clin Cancer Res 9:1680
16. McDonald GB, Slattery JT, Bouvier ME, Ren S, Batchelder AL, Kalhorn TF, Schoch HG, Anasetti C, Gooley T (2003) Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood 101:2043
17. Monshouwer M, Witkamp RF, Nujmeijer SM, Van Amsterdam JG, Van Miert AS (1996) Suppression of cytochrome P450- and UDP glucuronosyl transferase- dependent enzyme activities by proinflammatory cytokines and possible role of nitric oxide in primary cultures of pig hepatocytes. Toxicol Appl Pharmacol 137:237
18. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G (1993) Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 177:1675
19. Paxton JW, Kestell P, Ding Q, Ching L-M, Palmer BD, Zhou S, Baguley BC (2002) Investigations into the modulation of the pharmacokinetics of cyclophosphamide by thalidomide in mice. Proceedings of the Australian Health and Medical Research Congress, Melbourne, Australia, 2121a
20. Rewcastle GW, Atwell GJ, Baguley BC, Boyd M, Thomsen LL, Zhuang L, Denny WA (1991) Potential antitumor agents. 63. Structure-activity relationships for side-chain analogues of the colon 38 active agent 9-oxo-9H-xanthene-4-acetic acid. J Med Chem 34:2864
21. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeddis J, Barlogie B (1999) Antitumor activity of thalidomide in refractory multiple myeloma. New Engl J Med 341:1565
22. Turk BE, Jiang H, Liu JO (1996) Binding of thalidomide to alpha1-acid glycoprotein may be involved in its inhibition of tumor necrosis factor alpha production. Proc Natl Acad Sci U S A 93:7552
23. Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R (2003) Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 21:16
24. Webster LK, Ellis AG, Kestell P, Rewcastle GW (1995) Metabolism and elimination of 5,6-dimethylxanthenone-4-acetic acid in the isolated perfused rat liver. Drug Metab Dispos 23:363
25. Yu LJ, Drewes P, Gustafsson K, Brain EG, Hecht JE, Waxman DJ (1999) In vivo modulation of alternative pathways of P-450-catalyzed cyclophosphamide metabolism: impact on pharmacokinetics and antitumor activity. J Pharmacol Exp Ther 288:928
26. Zhao L, Ching LM, Kestell P, Baguley BC (2002) The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice. Br J Cancer 87:465
27. Zhao L, Kestell P, Ching LM, Baguley BC (2002) Oral activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice. Cancer Chemother Pharmacol 49:20
28. Zhou S, Paxton JW, Kestell P, Tingle MD, Ching LM (2001) In vitro and in vivo kinetic interactions of the antitumour agent 5,6-dimethylxanthenone-4- acetic acid with thalidomide and diclofenac. Cancer Chemother Pharmacol 47:319